Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Advanced Metastatic Breast Cancer

In brief

The purpose of this study was to determine whether treatment with tamoxifen or a non-steroidal aromatase inhibitors (NSAI) + goserelin + LEE011 prolonged progression-free survival (PFS) compared to treatment with tamoxifen or a NSAI + goserelin + placebo in premenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Key facts

Study ID
NCT02278120
Run by
Novartis Pharmaceuticals
People needed
672
Starts
2014-11-20
Expected to finish
2023-04-20
Last updated by the study team
2024-03-12

Who can join

Age: 18 and older, up to 59. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.